-
Product Insights
NewLeucine Rich Repeat Kinase – Drugs In Development, 2024
The Leucine Rich Repeat Kinase pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Oncology, and Ophthalmology which include indications of Parkinson's Disease, Unspecified Neurologic Disorders, Crohn's Disease (Regional Enteritis), Pancreatic Cancer, Glioblastoma Multiforme (GBM), Ocular Hypertension, and Open-Angle Glaucoma....
-
Product Insights
NewLeucine Rich Repeat Containing Protein 32 – Drugs In Development, 2024
The Leucine Rich Repeat Containing Protein 32 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Containing Protein 32 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Non-Small Cell Lung Cancer. It also reviews key players involved in Leucine Rich Repeat Containing Protein 32 targeted...
-
Product Insights
NewMyristoylated Alanine Rich C Kinase Substrate – Drugs In Development, 2024
The Myristoylated Alanine Rich C Kinase Substrate pipeline drugs market research report outlays comprehensive information on the Myristoylated Alanine Rich C Kinase Substrate targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Oncology, Respiratory, and Immunology which include indications of Uveitis, Lung Cancer, Pediatric Cancer, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease (COPD), and Psoriasis. It...
-
Product Insights
NewLeucine Rich Repeat Serine/Threonine Protein Kinase 2 – Drugs In Development, 2024
The Leucine Rich Repeat Serine/Threonine Protein Kinase 2 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Gastrointestinal, Oncology, and Ophthalmology which include indications of Parkinson's Disease, Unspecified Neurologic Disorders, Crohn's Disease (Regional Enteritis), Pancreatic Cancer, Glioblastoma Multiforme...
-
Product Insights
NewLeucine Rich Repeat Containing G Protein Coupled Receptor 5 – Drugs In Development, 2024
The Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Metastatic Colorectal Cancer. It also reviews key players involved in Leucine Rich...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in T-Cell Lymphomas Drug Details: Polatuzumab vedotin (Polivy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Drug Details: Polatuzumab...
-
Sector Analysis
NewSouth America Destination Tourism Trends Insight by Type, Source Markets, Foreign Direct Investment and Future Opportunities, 2024 Update
South America Destination Tourism Report Overview In 2023, international arrivals into South America reached 32.92 million travelers and will reach pre-pandemic levels in 2024. As per GlobalData, the number of international arrivals is anticipated to grow at a CAGR of more than 8% from 2023 to 2028. South America is well known for its natural attractions, with numerous iconic destinations such as Machu Picchu, the Galapagos Islands, the Iguazu Falls, and Patagonia. These locations offer a diverse range of experiences,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNA-3103 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CNA-3103 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CNA-3103 in Metastatic Colorectal Cancer Drug Details: CNA-3103 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAR20.19.22 T-cells in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAR20.19.22 T-cells in Burkitt Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAR20.19.22 T-cells in Burkitt Lymphoma Drug Details: Gene-modified cell therapy...